Induction of IL-1Ra in resistant and responsive hepatitis C patients following treatment with IFN-con1 - PubMed (original) (raw)

Induction of IL-1Ra in resistant and responsive hepatitis C patients following treatment with IFN-con1

Scott J Cotler et al. J Interferon Cytokine Res. 2002 May.

Abstract

Hepatitis C virus (HCV) infection is resistant to interferon-alpha (IFN-alpha) in some patients. The mechanism of this resistance is unknown. Interleukin-1 receptor antagonist (IL-1Ra) is induced by IFN-alpha and is a good indicator of IFN activity. In the current study, we compared IL-1Ra levels in rapid virologic responders and flat responders who showed resistance to IFN. Three groups of patients were examined, including those who received a single dose of consensus IFN (IFN-con1), patients who received daily IFN-con1 for 1 week, and patients who received IFN-con1 daily for 24 weeks. Serum IL-1Ra, IL-6, and HCV RNA were measured serially in all groups. Serum IL-1Ra levels increased rapidly in all patients with hepatitis C after IFN-alpha administration, irrespective of their virologic response. IL-1Ra levels remained elevated at 1 week but were similar to baseline by week 2 of treatment in patients receiving continuous therapy. IL-6 levels also increased acutely but rose more slowly than IL-1Ra levels. The increase in IL-1Ra and IL-6 observed in both flat and rapid virologic responders indicates that IFN receptors are functioning in patients with IFN-resistant hepatitis C and that the lack of response is related to other virologic or immunologic factors.

PubMed Disclaimer

Similar articles

• Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use.
  Antonelli G, Scagnolari C, Moschella F, Proietti E. Antonelli G, et al. Cytokine Growth Factor Rev. 2015 Apr;26(2):121-31. doi: 10.1016/j.cytogfr.2014.12.006. Epub 2014 Dec 30. Cytokine Growth Factor Rev. 2015. PMID: 25578520 Free PMC article. Review.
• An analysis of acute changes in interleukin-6 levels after treatment of hepatitis C with consensus interferon.
  Cotler SJ, Reddy KR, McCone J, Wolfe DL, Liu A, Craft TR, Ferris MW, Conrad AJ, Albrecht J, Morrissey M, Ganger DR, Rosenblate H, Blatt LM, Jensen DM, Taylor MW. Cotler SJ, et al. J Interferon Cytokine Res. 2001 Dec;21(12):1011-9. doi: 10.1089/107999001317205132. J Interferon Cytokine Res. 2001. PMID: 11798458 Clinical Trial.
• [Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
  Berg T, Kaul T, Naumann U, Wiedenmann B, Hopf U. Berg T, et al. Z Gastroenterol. 2000 Nov;38(11):881-6. doi: 10.1055/s-2000-10299. Z Gastroenterol. 2000. PMID: 11132533 Clinical Trial. German.
• Increased soluble IL-2 receptor levels during interferon and ribavirin treatment are associated with a good response in genotype 2a/2b patients with chronic hepatitis C.
  Abe S, Narita R, Matsuhashi T, Oto T, Tabaru A, Otsuki M. Abe S, et al. Eur J Gastroenterol Hepatol. 2008 May;20(5):373-8. doi: 10.1097/MEG.0b013e3282f43aae. Eur J Gastroenterol Hepatol. 2008. PMID: 18403937
• Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4.
  Zekri AR, Haleem HA, Esmat GE, Bahnassy AA, El-Din HM, Hafez MM, Sharaby AF, Sharaf H, Zakaria MS. Zekri AR, et al. J Viral Hepat. 2007 Jul;14(7):468-77. doi: 10.1111/j.1365-2893.2006.00832.x. J Viral Hepat. 2007. PMID: 17576388 Clinical Trial.

Cited by

• Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy.
  Taylor MW, Tsukahara T, Brodsky L, Schaley J, Sanda C, Stephens MJ, McClintick JN, Edenberg HJ, Li L, Tavis JE, Howell C, Belle SH. Taylor MW, et al. J Virol. 2007 Apr;81(7):3391-401. doi: 10.1128/JVI.02640-06. Epub 2007 Jan 31. J Virol. 2007. PMID: 17267482 Free PMC article.
• Type I IFN induced IL1-Ra expression in hepatocytes is mediated by activating STAT6 through the formation of STAT2: STAT6 heterodimer.
  Wan L, Lin CW, Lin YJ, Sheu JJ, Chen BH, Liao CC, Tsai Y, Lin WY, Lai CH, Tsai FJ. Wan L, et al. J Cell Mol Med. 2008 Jun;12(3):876-88. doi: 10.1111/j.1582-4934.2008.00143.x. J Cell Mol Med. 2008. PMID: 18494930 Free PMC article.
• Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use.
  Antonelli G, Scagnolari C, Moschella F, Proietti E. Antonelli G, et al. Cytokine Growth Factor Rev. 2015 Apr;26(2):121-31. doi: 10.1016/j.cytogfr.2014.12.006. Epub 2014 Dec 30. Cytokine Growth Factor Rev. 2015. PMID: 25578520 Free PMC article. Review.
• Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment.
  Taylor MW, Tsukahara T, McClintick JN, Edenberg HJ, Kwo P. Taylor MW, et al. J Transl Med. 2008 Nov 5;6:66. doi: 10.1186/1479-5876-6-66. J Transl Med. 2008. PMID: 18986530 Free PMC article.
• The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction.
  Thacker SG, Berthier CC, Mattinzoli D, Rastaldi MP, Kretzler M, Kaplan MJ. Thacker SG, et al. J Immunol. 2010 Oct 1;185(7):4457-69. doi: 10.4049/jimmunol.1001782. Epub 2010 Aug 30. J Immunol. 2010. PMID: 20805419 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon